PRX-102 (pegunigalsidase alfa)
PB-102-F03
Phase 3 mab completed
Quick answer
PRX-102 (pegunigalsidase alfa) for Fabry Disease is a Phase 3 program (mab) at Protalix BioTherapeutics with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Protalix BioTherapeutics
- Indication
- Fabry Disease
- Phase
- Phase 3
- Modality
- mab
- Status
- completed